ERBB2 and breast carcinoma: Another important field of adoption of ctDNA analysis in breast cancer patients is for the identification of ESR1 resistance mutations in ER‐positive, HER2‐negative breast cancer patients after endocrine therapy, with a digital droplet PCR (ddPCR) approach.